MooreKuehn.jpg
Moore Kuehn Encourages MTSC, SPRQ, NEOS, and PRSP Investors to Contact Law Firm
January 28, 2021 11:04 ET | Moore Kuehn
NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
PDF to PNG Logo.png
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Neos Therapeutics, Inc. Merger
December 11, 2020 10:38 ET | Rigrodsky & Long, P.A.
WILMINGTON, Del., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Neos Therapeutics, Inc. (“Neos”) (NASDAQ GS: NEOS) regarding possible breaches of...
Neos Therapeutics logo
Neos Therapeutics Announces Appointment of James Robinson to Board of Directors
January 30, 2019 08:00 ET | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics logo
Neos Therapeutics Announces Settlement with Teva on Cotempla XR-ODT® Patent Litigation
December 26, 2018 07:30 ET | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Dec. 26, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing innovative...
Neos Therapeutics logo
Neos Therapeutics Announces Realignment of Commercial Organization
November 30, 2018 07:30 ET | Neos Therapeutics, Inc.
– Strategic assessment leads to new salesforce structure and is expected to accelerate path to profitability –  – Company to host conference call today at 8:30am ET – DALLAS and FORT WORTH, Texas,...
Neos Therapeutics logo
Neos Therapeutics Reports Third Quarter 2018 Financial Results
November 09, 2018 07:00 ET | Neos Therapeutics, Inc.
Company to host conference call today at 8:30am ET  DALLAS and FORT WORTH, Texas, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a fully-integrated pharmaceutical...
Neos Therapeutics logo
Neos Therapeutics Announces Pricing of Underwritten Public Offering of $40 Million of Common Stock
November 06, 2018 09:21 ET | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and...
Neos Therapeutics logo
Neos Therapeutics Announces Proposed Offering of Common Stock
November 05, 2018 16:03 ET | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and...
Neos Therapeutics logo
Neos Therapeutics to Host Third Quarter 2018 Financial Results Conference Call on November 9, 2018
November 02, 2018 07:30 ET | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will report third quarter 2018 financial results prior to the opening...
Neos Therapeutics logo
Neos Therapeutics to Present New Data for ADHD Medication, Adzenys XR-ODT®, at the American Academy of Child & Adolescent Psychiatry Meeting
October 24, 2018 08:00 ET | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will present new data for Adzenys XR-ODT (amphetamine) Extended-Release...